Halia CEO, David Bearss, on Challenges Posed by FDA Project Optimus
September 5, 2024
Halia Therapeutics’ CEO, David Bearss, recently discussed the FDA’s Project Optimus in The Wall Street Journal. These new regulations pose significant challenges for smaller biopharma companies like Halia. They risk driving innovation overseas due to higher costs and longer timelines. Halia remains, however, committed to identifying the most effective, lowest doses in early trials to deliver safe and potent treatments to patients.
Recent News
- Peer-Reviewed Article Reporting DiscGenics’ Cell Therapy Phase I/II Study Results Receives International Journal of Spine Surgery Best Paper Award
- BREAKING GROUND ON COMPREHENSIVE CANCER CENTER IN VINEYARD
- The ‘Father of Modern Food and Drug Law,’ Peter Hutt, Joins EVŌQ Nano Board of Directors
- Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries
- Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas
- Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
